TY - JOUR
T1 - Evaluation of the treatment modalities for neurosensory disturbances of the inferior alveolar nerve following retromolar bone harvesting for bone augmentation
AU - Nogami, Shinnosuke
AU - Yamauchi, Kensuke
AU - Shiiba, Shunji
AU - Kataoka, Yoshihiro
AU - Hirayama, Bunichi
AU - Takahashi, Tetsu
N1 - Publisher Copyright:
© 2015 American Academy of Pain Medicine.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - Subjects: The purpose of this study was to evaluate the treatment modalities for neurosensory disturbances (NSDs) of the inferior alveolar nerve occurring after retromolar bone harvesting for bone augmentation procedures before implant placement. Methods: One hundred four patients, of which 49 and 55 exhibited vertical or horizontal alveolar ridge defects in the mandible and maxilla, respectively, were enrolled. Nineteen patients underwent block bone grafting, 38 underwent guided bone generation or autogenous bone grafting combined with titanium mesh reconstruction, and 47 underwent sinus floor augmentation. Using a visual analog scale, we examined subjective symptoms and discomfort related to sensory alteration within the area of the NSDs in these patients. NSDs were clinically investigated using a two-point discrimination test with blunt-tipped calipers. In addition, neurometry was used for evaluation of trigeminal nerve injury. We tested three treatment modalities for NSDs: follow-up observation (no treatment), medication, and stellate ganglion block (SGB). Results: A week after surgery, 26 patients (25.0%) experienced NSDs. Five patients received no treatment, 10 patients received medication, and 11 patients received SGB. Three months after surgery, patients in the medication and SGB group achieved complete recovery. Current perception threshold values recovered to near-baseline values at 3 months: recovery was much earlier in this group than in the other two groups. SGB can accelerate recovery from NSDs. Conclusions: Our results justify SGB as a reasonable treatment modality for NSDs occurring after the harvesting of retromolar bone grafts.
AB - Subjects: The purpose of this study was to evaluate the treatment modalities for neurosensory disturbances (NSDs) of the inferior alveolar nerve occurring after retromolar bone harvesting for bone augmentation procedures before implant placement. Methods: One hundred four patients, of which 49 and 55 exhibited vertical or horizontal alveolar ridge defects in the mandible and maxilla, respectively, were enrolled. Nineteen patients underwent block bone grafting, 38 underwent guided bone generation or autogenous bone grafting combined with titanium mesh reconstruction, and 47 underwent sinus floor augmentation. Using a visual analog scale, we examined subjective symptoms and discomfort related to sensory alteration within the area of the NSDs in these patients. NSDs were clinically investigated using a two-point discrimination test with blunt-tipped calipers. In addition, neurometry was used for evaluation of trigeminal nerve injury. We tested three treatment modalities for NSDs: follow-up observation (no treatment), medication, and stellate ganglion block (SGB). Results: A week after surgery, 26 patients (25.0%) experienced NSDs. Five patients received no treatment, 10 patients received medication, and 11 patients received SGB. Three months after surgery, patients in the medication and SGB group achieved complete recovery. Current perception threshold values recovered to near-baseline values at 3 months: recovery was much earlier in this group than in the other two groups. SGB can accelerate recovery from NSDs. Conclusions: Our results justify SGB as a reasonable treatment modality for NSDs occurring after the harvesting of retromolar bone grafts.
KW - Inferior alveolar nerve
KW - Neurosensory disturbances
KW - Stellate ganglion block
UR - http://www.scopus.com/inward/record.url?scp=84925293215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925293215&partnerID=8YFLogxK
U2 - 10.1111/pme.12618
DO - 10.1111/pme.12618
M3 - Article
C2 - 25533572
AN - SCOPUS:84925293215
SN - 1526-2375
VL - 16
SP - 501
EP - 512
JO - Pain Medicine
JF - Pain Medicine
IS - 3
ER -